Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Beth Israel Deaconess Medical Center
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07654426CT.gov The CARDIOPROTECT Trial | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Heart Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Polatuzumab Vedotin (this asset) | Beth Israel Deaconess Medical Center | P2 | CCC · 53 |
| Potassium | Tufts Medical Center | P3 | BB |
| Orlistat | University of British Columbia | P4 | BB |
| Acoramidis | Eidos Therapeutics, a BridgeBio company | P3 | BB |
| Carvedilol | Abramson Cancer Center at Penn Medicine | P3 | BB |
| Warfarin | Massachusetts General Hospital | P3 | BB |
| Ticagrelor | Assistance Publique - Hôpitaux de Paris | P3 | B |
| Captopril | Children's Cancer Hospital Egypt 57357 | P3 | B |
| Beatrolol | University of Sao Paulo | P3 | B |
+26 more in the Heart Disorder cohort
Other indications for Polatuzumab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 69 |
| Non-Hodgkin Lymphoma | — | P3 | BB · 65 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Polatuzumab Vedotin in Heart Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/polatuzumab-vedotin-heart-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →